{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:05:28Z","timestamp":1785477928485,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The percentage of hypochromic red blood cells (%HRC) estimates the availability of iron by evaluating the degree of hemoglobinization. We investigated whether %HRC was a predictor of anemia in patients undergoing hemodialysis. We recruited 142 patients undergoing routine hemodialysis between 2017 and 2019. Delta hemoglobin level (\u0394Hb)\n                    <jats:sub>1mo-baseline<\/jats:sub>\n                    was calculated as the difference between the hemoglobin level at 1\u00a0month after study enrollment and that at the time of study enrollment. Development of anemia was defined as hemoglobin level\u2009\u2264\u200915% of baseline. The median %HRC was 3.1%. There was a significant negative correlation between (\u0394Hb)\n                    <jats:sub>1mo- baseline<\/jats:sub>\n                    and %HRC (r\u2009=\u2009\u2009\u2212\u20090.63,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). The incidence of anemia was significantly higher in patients with %HRC\u2009&gt;\u20093.1% than in those with %HRC\u2009\u2264\u20093.1%. In the multivariate logistic regression analysis, %HRC was significantly related to the development of anemia (odds ratio 2.57, 95% confidence interval [CI] 1.72\u20133.85,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). The best cutoff value for %HRC to predict the development of anemia was 4.3%, with a sensitivity and specificity of 67.74 (95% CI, 54.7\u201379.1) and 97.50 (95% CI, 91.3\u2013 99.7), respectively. %HRC is an independent predictor of anemia in patients undergoing hemodialysis. %HRC\u2009\u2264\u20094.3% is an early marker to consider changing the anemia treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-03746-2","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T06:13:41Z","timestamp":1639980821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypochromic red cells as predictors of anemia in patients undergoing hemodialysis: an observational retrospective study"],"prefix":"10.1038","volume":"11","author":[{"given":"Youn Kyung","family":"Kee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"3746_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ki.1989.18","volume":"35","author":"JW Eschbach","year":"1989","unstructured":"Eschbach, J. W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 35, 134\u2013148 (1989).","journal-title":"Kidney Int."},{"key":"3746_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1309\/AJCPQAX0JFHFS0OA","volume":"133","author":"M Buttarello","year":"2010","unstructured":"Buttarello, M. et al. Diagnosis of iron deficiency in patients undergoing hemodialysis. Am. J. Clin. Pathol. 133, 949\u2013954 (2010).","journal-title":"Am. J. Clin. Pathol."},{"key":"3746_CR3","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","volume":"58","author":"RN Foley","year":"2000","unstructured":"Foley, R. N. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 58, 1325\u20131335 (2000).","journal-title":"Kidney Int."},{"key":"3746_CR4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/ndt\/gfl558","volume":"22","author":"J Portol\u00e9s","year":"2007","unstructured":"Portol\u00e9s, J., L\u00f3pez-G\u00f3mez, J. M. & Aljama, P. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: The MAR Study. Nephrol. Dial. Transplant. 22, 500\u2013507 (2007).","journal-title":"Nephrol. Dial. Transplant."},{"key":"3746_CR5","first-page":"345","volume":"20","author":"AJ Collins","year":"2000","unstructured":"Collins, A. J., Ma, J. Z. & Ebben, J. Impact of hematocrit on morbidity and mortality. Semin. Nephrol. 20, 345\u2013349 (2000).","journal-title":"Semin. Nephrol."},{"key":"3746_CR6","doi-asserted-by":"crossref","first-page":"c95","DOI":"10.1159\/000345158","volume":"121","author":"J Vinhas","year":"2012","unstructured":"Vinhas, J., Barreto, C., Assun\u00e7\u00e3o, J., Parreira, L. & Vaz, A. Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: A meta-analysis. Nephron Clin. Pract. 121, c95-101 (2012).","journal-title":"Nephron Clin. Pract."},{"key":"3746_CR7","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1046\/j.1523-1755.2003.00937.x","volume":"63","author":"N Ofsthun","year":"2003","unstructured":"Ofsthun, N., Labrecque, J., Lacson, E., Keen, M. & Lazarus, J. M. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 63, 1908\u20131914 (2003).","journal-title":"Kidney Int."},{"key":"3746_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","volume":"153","author":"SC Palmer","year":"2010","unstructured":"Palmer, S. C. et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann. Intern. Med. 153, 23\u201333 (2010).","journal-title":"Ann. Intern. Med."},{"key":"3746_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","volume":"62","author":"AS Kliger","year":"2013","unstructured":"Kliger, A. S. et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am. J. Kidney Dis. 62, 849\u2013859 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"3746_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.semnephrol.2016.02.002","volume":"36","author":"J Bahrainwala","year":"2016","unstructured":"Bahrainwala, J. & Berns, J. S. Diagnosis of Iron-deficiency anemia in chronic kidney disease. Semin. Nephrol. 36, 94\u201398 (2016).","journal-title":"Semin. Nephrol."},{"key":"3746_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","volume":"31","author":"EK Batchelor","year":"2020","unstructured":"Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P. & Jalal, D. I. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J. Am. Soc. Nephrol. 31, 456\u2013468 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3746_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/clinchem\/48.7.1066","volume":"48","author":"C Thomas","year":"2002","unstructured":"Thomas, C. & Thomas, L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin. Chem. 48, 1066\u20131076 (2002).","journal-title":"Clin. Chem."},{"key":"3746_CR13","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt, J. L. & Lin, H. Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23, 1631\u20131634 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3746_CR14","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69044.x","volume":"69","author":"RM Schaefer","year":"1999","unstructured":"Schaefer, R. M. & Schaefer, L. Hypochromic red blood cells and reticulocytes. Kidney Int. Suppl. 69, S44-48 (1999).","journal-title":"Kidney Int. Suppl."},{"key":"3746_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12882-020-01796-8","volume":"21","author":"NH Dinh","year":"2020","unstructured":"Dinh, N. H., Cheanh Beaupha, S. M. & Tran, L. T. A. The validity of reticulocyte hemoglobin content and percentage of hypochromic red blood cells for screening iron-deficiency anemia among patients with end-stage renal disease: A retrospective analysis. BMC Nephrol. 21, 142 (2020).","journal-title":"BMC Nephrol."},{"key":"3746_CR16","doi-asserted-by":"publisher","first-page":"e0204899","DOI":"10.1371\/journal.pone.0204899","volume":"13","author":"AM Nalado","year":"2018","unstructured":"Nalado, A. M. et al. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One 13, e0204899 (2018).","journal-title":"PLoS One"},{"key":"3746_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/ki.1997.323","volume":"52","author":"S Fishbane","year":"1997","unstructured":"Fishbane, S., Galgano, C., Langley, R. C. Jr., Canfield, W. & Maesaka, J. K. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 52, 217\u2013222 (1997).","journal-title":"Kidney Int."},{"key":"3746_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000245041","volume":"29","author":"M Kanbay","year":"2010","unstructured":"Kanbay, M., Perazella, M. A., Kasapoglu, B., Koroglu, M. & Covic, A. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: Review of causes and management. Blood Purif. 29, 1\u201312 (2010).","journal-title":"Blood Purif."},{"key":"3746_CR19","doi-asserted-by":"publisher","first-page":"603786","DOI":"10.1155\/2013\/603786","volume":"2013","author":"E Urrechaga","year":"2013","unstructured":"Urrechaga, E., Borque, L. & Escanero, J. F. Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis. Biomed. Res. Int. 2013, 603786 (2013).","journal-title":"Biomed. Res. Int."},{"key":"3746_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ndt\/14.3.659","volume":"14","author":"P Cullen","year":"1999","unstructured":"Cullen, P. et al. Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol. Dial. Transplant. 14, 659\u2013665 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"3746_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","volume":"16","author":"N Tessitore","year":"2001","unstructured":"Tessitore, N. et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol. Dial. Transplant. 16, 1416\u20131423 (2001).","journal-title":"Nephrol. Dial. Transplant."},{"key":"3746_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.ajkd.2015.11.012","volume":"67","author":"LE Ratcliffe","year":"2016","unstructured":"Ratcliffe, L. E. et al. Diagnosis and management of iron deficiency in CKD: A summary of the NICE guideline recommendations and their rationale. Am. J. Kidney Dis. 67, 548\u2013558 (2016).","journal-title":"Am. J. Kidney Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03746-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:11:29Z","timestamp":1670073089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03746-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-870840\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24215"}}